Celltrion Nearly Triples Production Capability For Biosimilars In Anticipation Of Global Launches
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's biosimilar front-runner Celltrion, Inc. will begin production at a new 90,000-liter manufacturing plant Oct. 5 located at its main plant in Incheon City